Last reviewed · How we verify
NCT05611658
Inter-observer Variation in Gross Tumor Delineation of Esophageal Cancer on MR, CT and PET CT
trial testing MR, PET CT in Esophageal Cancer in 23 participants. Completed in 30 September 2023.
25 May 2021
Quick facts
| Lead sponsor | Institute of Oncology Ljubljana |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 23 |
| Start date | 20 May 2020 |
| Primary completion | 25 May 2021 |
| Estimated completion | 30 September 2023 |
| Sites | 1 location across Slovenia |
Drugs / interventions tested
- MR, PET CT
Conditions studied
- Esophageal Cancer — all drugs for Esophageal Cancer →
Sponsor
Institute of Oncology Ljubljana
Who can join
18 and older, any sex, with Esophageal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the study is to investigate inter-observer variation in gross tumor volume (GTV) delineation of oesophageal cancer on different imaging modalities - CT, PET CT and MR.Twenty-three consecutive patients with esophageal cancer treated with preoperative or curative chemoradiotherapy were selected. All patients had CT, PET CT and MR imaging in treatment position prior to radiotherapy.Five experienced observers from our institution will independently delineate GTV on CT alone, MR alone, PET CT alone, on co-registered CT and MR and co-registered PET CT and MR. Inter-observer agreement, expressed in generalized conformity index (CIgen) and mean volumes of GTV will be calculated per patient and imaging modality.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Inter-observer variation in gross tumour volume delineation of oesophageal cancer on MR, CT and PET/CT.
Secerov-Ermenc A, Peterlin P, Anderluh F, But-Hadzic J, et al · · 2024 · cited 2× · PMID 39362222 · DOI 10.2478/raon-2024-0043 -
PET/CT and MR Improve Interobserver Agreement in Primary Tumor Determination for Radiotherapy in Esophageal Squamous Cell Cancer.
Secerov-Ermenc A, Peterlin P, Velenik V, Jeromen-Peressutti A, et al · · 2025 · PMID 40150033 · DOI 10.3390/diagnostics15060690
Verify or expand the search:
- PubMed search for NCT05611658
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Esophageal Cancer
Currently open trials in the same condition.
- NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
- NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
- NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07307560 — High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients · NA · recruiting
Other Institute of Oncology Ljubljana trials
Trials by the same sponsor.
- NCT06923787 — Effect of Perioperative Intravenous Infusion of Lidocaine on the Postoperative Course and the Immune Response in Patient · Phase 2 · recruiting
- NCT07432399 — Effect of Perioperative Lidocaine or High-Dose Dexamethasone on Immune Response in Colon Cancer Surgery (PILDI Study) · Phase 2 · recruiting
- NCT06650423 — Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer · recruiting
- NCT07420647 — Pilot Study of Individualized Treatment for Genitourinary Syndrome of Menopause in Women After Cancer Treatment · NA · active not recruiting
- NCT07416500 — BRCA1, RASSF1A and PTEN Methylation in Breast Lesions of Uncertain Malignant Potential · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05611658 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institute of Oncology Ljubljana
- Last refreshed: 17 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05611658.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing